The role of the old and the new antiepileptic drugs in special populations: Mental and multiple handicaps

Epilepsia

Volumn 37, Issue SUPPL. 6, 1996, Pages

  Mattson, Richard H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsants; Child development disorders; Drug interactions; Drug monitoring; Drug therapy; Drug toxicity; Epilepsy; Mental retardation; Psychotropic drugs

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ALOPECIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; CONFERENCE PAPER; DISABILITY; DISEASE ASSOCIATION; DRUG EFFICACY; FOCAL EPILEPSY; GINGIVA HYPERPLASIA; HUMAN; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; MENTAL DEFICIENCY; NEUROTOXICITY; PRIORITY JOURNAL; RASH; STEVENS JOHNSON SYNDROME; TREATMENT PLANNING; WEST SYNDROME;

EID: 0029852653     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb06039.x     Document Type: Conference Paper

References (82)

1. American Psychiatric Association. Disorders usually first diagnosed in infancy, childhood, or adolescence. In: Diagnostic and Statistical Manual of Mental Disorders (DSM IV). 4th ed. Washington, DC: American Psychiatric Association; 1994:37-90.
2. Brodtkrob E. The diversity of epilepsy in adults with severe developmental disabilities: age at seizure onset and other prognostic factors. Seizure 1994;3:277-85.
3. Coulter DL. Epilepsy and mental retardation: an overview. Am J Ment Retard 1993;98(suppl):1-11.
4. Dodson WE, Pellock JM, eds. Epilepsy and I.Q. New York: Demos Publishers; 1992:373-85.
5. Jenkins LK, Brown SW. Some issues in the assessment of epilepsy occurring in the context of learning disability in adults. Seizure 1992;1:49-55.
6. Marcus JC. Control of epilepsy in a mentally retarded population: lack of correlation with IQ, neurological status, and electroencephalogram. Am J Ment Retard 1993;98(suppl):47-51.
7. Mariani E, Ferini-Strambi L, Sala M, Erminio C, Smirne S. Epilepsy in institutionalized patients with encephalopathy: clinical aspects and nosological considerations. Am J Ment Retard 1993;98(suppl):27-33.
8. Nevo Y, Shinnar S, Samuel E, et al. Unprovoked seizures and developmental disabilities: clinical characteristics of children referred to a child development center. Pediatr Neurol 1995;13:235-41.
9. Pary R. Mental retardation, mental illness, and seizure diagnosis. Am J Ment Retard 1993;89(suppl):58-62.
10. Pellock JM, Hunt PA. A decade of modern epilepsy therapy in institutionalized mentally retarded patients. Epilepsy Res (in press).
11. Sillapanpaa M. Epilepsy in children: prevalence, disability, and handicap. Epilepsy 1992;33:444-9.
12. Wong V. Epilepsy in children with autistic spectrum disorder. J Child Neurol 1993;8:316-22.
13. Meador KJ, Loring DW, Hun K, Gallagher BB, King DW. Comparative cognitive effects of anticonvulsants. Neurology 1990;40:391-4.
14. Vining EG, Mellits ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987;80:165-74.
15. Wolf SM, Can A, Davis DC, Davison S. The value of phenobarbital in the child who has had a single febrile seizure. Pediatrics 1977;59:378-83.
16. Corbett J. Epilepsy as part of a handicapping condition. In: Ross E, Reynolds E, eds. Paediatric perspectives on epilepsy. London, UK: John Wiley & Sons Ltd; 1985:79-89.
17. Hogg J. The administration of psychotropic and anticonvulsant drugs to children with profound intellectual disability and multiple impairments. J Intellect Disabil Res 1992;36:473-88.
18. Mirza WU, Credeur LJ, Penry JK. Results of antiepileptic drug reduction in patients with multiple handicaps and epilepsy. Drug Invest 1993;5:320-6.
19. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:498-501.
20. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
21. Fischbacher E. Effect of reduction of anticonvulsants on wellbeing. BMJ 1982;285:423-4.
22. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991;41:961-4.
23. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995:36(suppl 2):S12-26.
24. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:756-71.
25. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
26. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985;313:916-21.
27. DeSilva MB, McGowan M, Neville BR, Johnson AL, Reynolds EH. A prospective randomised comparative monotherapy clinical trials in childhood epilepsy. In: Chadwick E, ed. Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy. London, UK: Royal Society of Medicine Services Ltd; 1989:81-6.
28. Dodson WE. Carbamazepine efficacy and utilization in children. Epilepsia 1987;28(suppl 2):S17-24.
29. Heller AJ, Chesterman P, Elwes RC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomized comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995;58:44-50.
30. Richens A, Davison DW. Cartlidge NE, et al. A multicenter comparative trial of sodium valproale and carbamazepine in adult-onset epilepsy. J Neurol Neurosurg Psychiatry 1994;57:682-7.
31. Troupin AS, Ojeman LM, Halpern LM, Dodril C, Wilkus R, Friel P. Carbamazepine: a controlled double-blind comparison with phenytoin. Neurology 1977;27:511-9.
32. Felbamate Study Group. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328:29-33.
33. Brodie MJ, Richens A, Yuen AC, et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
34. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in pa- tients with newly diagnosed epilepsy. A randomized controlled study. Arch Neurol 1995;52:989-96.
35. Brodie MJ, Pellock JM. Taming the brainstorms: felbamate updated. Lancet 1995;346:918-9.
36. Timmings PL, Richens A. Lamotrigine as add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992;32:305-7.
37. Uvebrant P, Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-9.
38. Besag FC, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-7.
39. Lombroso CT. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983;24:135-8.
40. Aicardi J, Sabril IS Investigator and Peer Review Groups, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective study. Epilepsy 1996;37:638-42.
41. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991;6(suppl 2):S52-9.
42. Dulac O, Chiron C, Luna D, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1992;7(suppl 2):S30-7.
43. Aman MG, Sarphare G, Burrow WH. Psychotropic drugs in group homes: prevalence and relation to demographic psychiatric variables. Am J Ment Retard 1995;99:500-9.
44. Beghi E, Bollin P, DiMascio R, Cernosola N, Meloni T, Manghi E. Effects of rationalizing drug treatment of patients with epilepsy and mental retardation. Dev Med Child Neurol 1987;29:363-9.
45. Sheppard LC, Ballinger BR, Fenton GW. Anticonvulsant medication in a mental handicapped hospital. Br J Psychiatry 1972-82.
46. Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987;28(suppl 3):S37-45.
47. Herranz JL, Armijo JA, Artega R. Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsy 1988;29:794-804.
48. Brodtkrob E, Sand T, Strandjord RE. Neuroleptic and antiepileptic treatment in the mentally retarded. Seizure 1993;205-11.
49. Poindexter AR, Berglund JA, Kolstoe PD. Changes in antiepileptic drug prescribing patterns in large institutions: preliminary results of a five-year experience. Am J Ment Retard 1993;98:34-40.
50. Wilkinson IA, Murphy JV, Georgeson R, Disouza BJ. On site seizure clinic impact on the welfare of mentally retarded institutionalized patients. Arch Neurol 1982;39:41-3.
51. Bruni J. Phenytoin: toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th edition. New York: Raven Press; 1995:345-50.
52. Holmes GL. Carbamazepine toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th edition. New York: Raven Press; 1995:567-80.
53. Mattson RH, Cramer JA, Collins JI. Early tolerance to antiepileptic drug side effects: a controlled trial of 247 patients. In: Frey HH, Fröscher W, Koella WP, Meinardi H, eds. Tolerance to beneficial and adverse effects of antiepileptic drugs. New York: Raven Press; 1986:149-56.
54. Brodie MD, McKee PW. Vigabatrin and psychosis. Lancet 1990;335:1279.
55. Matilainen R, Pitkanen A, Routiainen T, Mervla E, Sarlund H, Riekinen P. Vigabatrin in epilepsy in mentally retarded patients. Neurology 1988;38:743-7.
56. Pitkanen A, Ylinen A, Matilainen R, et al. Long-term antiepileptic efficacy of vigabatrin in drug-refractory epilepsy in mentally retarded patients. A 5-year follow-up study. Arch Neurol 1993;50:24-9.
57. Tallian KB, Nahata MC, Lo W, Tssao C. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996;37:501.
58. Sander JS, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991;54:435-9.
59. Wolf SM, Shinnar S, Kang H, Gil K, Moshe S. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1996;36:1203-5.
60. Richens A. Lamotrigine toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th edition. New York: Raven Press; 1995:897-902.
61. Ettinger AB, Jandorf L, Berdia A, Andriola MR, Krupp LB, Weisbrot DM. Felbamate-induced headache. Epilepsia 1996;37:503.
62. Ben-Menachem E, Heriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
63. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities. II: U.S. experience since 1984. Neurology 1988;38:201-7.
64. Gidal B, Spencer N, Maly M, et al. Valproate-mediated disturbances of hemostasis. Neurology 1994;30:354.
65. Loiseau P. Sodium valproate, platelet dysfunction and bleeding. Epilepsia 1981;22:141-6.
66. Verity CM, Hosking G, Easter DJ. A multicenter comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995;37:97-100.
67. Dinesen H, Gram L, Anderson T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-9.
68. Mattson RH, Cramer JA, McCutchen CB, and the VA Cooperative Study Group. Barbiturate related connective tissue disorder. Arch Intern Med 1989;149:911-4.
69. Schmidt D. Connective tissue disorders induced by antiepileptic drugs. In: Oxley J, Janz D, Meinardi H, eds. Chronic toxicity of antiepileptic drugs. New York: Raven Press; 1983:115-24.
70. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3272-7.
71. Hoppener RJ, Kuyer A, Mayer A, Hulsman JA. Correlation between daily functions of carbamazepine serum levels and intermittent side effects. Epilepsia 1980;21:341-50.
72. Mattson GF, Mattson RH, Cramer JA. Interaction between valproic acid and carbamazepine. An in vitro study of protein binding. Ther Drug Monit 1982;4:181-4.
73. Mattson RH. Antiepileptic drug monitoring: a reappraisal. Epilepsia 1995;36(suppl 5):S22-9.
74. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986;256:238-40.
75. Mattson RH. Parenteral antiepileptic/anticonvulsant drugs. Neurology 1996;46(suppl 1):S8-13.
76. Kriel R, Cloyd J, Erdmann G, Crandall H. Pilot study: bioavailability of three rectal gel formulations versus parenteral diazepam solution given intravenously and rectally. 1990.
77. Rosman NP, Colton T, Labazzo J, et al. A controlled trial of diazepam administered during febrile illness to prevent recurrence of febrile seizures. N Engl J Med 1993;329:79-82.
78. Bell WL, Crawford IL, Shiu GK. Reduced bioavailability of moisture-exposed carbamazepine resulting in status epilepticus. Epilepsia 1993;34:1102-4.
79. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 1992;9:1612-6.
80. Nuwer M, Browne TR, Dodson EW, et al. Generic substitutes for antiepileptic drugs. Neurology 1990;40:1647-51.
81. Litzinger MJ, Duvall B, Little P. Movement of individuals with complex epilepsy from an institution into the community: seizure control and functional outcomes. Am J Ment Retard 1993;98(suppl):52-7.
82. Haakarinen H. Carbamazepine and phenytoin as monotherapy in treatment of adult epilepsy (Abstract). Neurology 1980;30:354.